Alzheimer’s diagnosis revamp embraces rating scale similar to cancer

Published July 17, 2023
A MARCH 30 file photo shows Dr Seth Gale pointing out evidence of Alzheimer’s disease on scans at the Centre for Alzheimer Research and Treatment at Brigham And Women’s Hospital in Boston, Massachusetts, US.—Reuters
A MARCH 30 file photo shows Dr Seth Gale pointing out evidence of Alzheimer’s disease on scans at the Centre for Alzheimer Research and Treatment at Brigham And Women’s Hospital in Boston, Massachusetts, US.—Reuters

Amsterdam: Alzhei­mer’s disease experts are revamping the way doctors diagnose patients with the progressive brain disorder — the most common type of dementia — adopting a seven-point rating scale based on cognitive and biological changes in the patient.

The new guidelines, unveiled by experts on Sunday in a report issued at an Alzheimer’s Association conference in Amsterdam, embrace a numerical staging system assessing disease progression similar to the one used in cancer diagnoses. They also eliminate the use of terms like mild, moderate and severe.

The revamp — replacing guidelines issued in 2018 — was prompted by the increased availability of tests detecting key Alzheimer’s-related proteins such as beta amyloid in the blood and new treatments that require confirmation of disease pathology prior to use.

The 2018 guidelines, which were intended for research use, incorporated existing technologies for detecting Alzheimer’s proteins based on PET scans of the brain and tests of cerebrospinal fluid, which were only accessible via a lumbar puncture. Such tests were costly and not typically used in standard medical practice.

The new system is designed to be more accurate and better reflect a person’s underlying disease, according to Dr Clifford Jack of the Mayo Clinic in Rochester, Minnesota, lead author of the report sponsored by the Alzheimer’s Association and the National Institute of Aging, a part of the US government’s National Institutes of Health.

The change comes at a time when doctors are preparing to identify and treat patients with Eisai and Biogen’s drug Leqembi, which won Food and Drug Administration approval this month, and Eli Lilly’s experimental drug donanemab, which is now under FDA review.

Published in Dawn, July 17th, 2023

Opinion

Editorial

Budget and politics
14 Jun, 2024

Budget and politics

FINANCE MINISTER Muhammad Aurangzeb on Thursday expressed his ‘resolve’ to increase Pakistan’s tax-to-GDP ...
New talks?
14 Jun, 2024

New talks?

WILL this prove another false start, or may we expect a more sincere effort this time? Reference is made to the...
A non-starter
14 Jun, 2024

A non-starter

WHILE the UN Security Council had earlier this week adopted a US-backed resolution calling for a ceasefire in Gaza...
Budget for stabilisation
Updated 13 Jun, 2024

Budget for stabilisation

The proposed steps lack any “disruptive policy changes", especially to "right-size" the govt, and doubts remain on authorities' ability to enforce new measures.
State of the economy
13 Jun, 2024

State of the economy

THE current fiscal year is but another year lost. Going by the new Pakistan Economic Survey, which maps the state of...
Unyielding onslaught
Updated 13 Jun, 2024

Unyielding onslaught

SEVEN soldiers paid the ultimate price in Lakki Marwat on Sunday when their vehicle was blown up in an IED attack,...